Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC)…
AISIX Solutions Inc. and Re: Drying Equipment Inc. Announce Update to Proposed Reverse Takeover Transaction
Arkansas Governor Sarah Huckabee Sanders Visits CoorsTek Benton Facility
ImagineAR Announces Agreement to Acquire s3iai Inc.
ANK Constructions & Interiors Launches No-Cost Snagging Inspections for Dubai Property Owners
NamSys Announces Normal Course Issuer Bid